Friday, 17 Aug 2018

You are here

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines (CPGs) from the American College of Rheumatology (ACR) are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. (Citation source: https://buff.ly/2AlfUPK)

Researchers compiled eight published rheumatology CPGs endorsed by the ACR and studied the the level of evidence and strength of the recommendations.  

Specifically this included clinical practice guidelines covering glucocorticoid-induced osteoporosis (GIOP), juvenile idiopathic arthritis (JIA), gout, lupus nephritis, osteoarthritis (OA), ankylosing spondylitis (SpA), polymyalgia rheumatica (PMR), and rheumatoid arthritis (RA). 

These 8 guidelines included 403 recommendations, with more than half (58%) based on level C evidence (meaning on expert opinion, case studies, or standard of care).

Importantly, only 23% of these recommendations were based on level A evidence (based on multiple randomized clinical trials or meta-analyses); and one-fifth were level B (single RCT or nonrandomized studies).

The proportion of recommendations supported by A-level evidence ranged from 2% for juvenile idiopathic arthritis and 10% for polymyalgia rheumatica to 35% for glucocorticoid-induced osteoporosis and 58% for osteoarthritis.

Obviously, societal guidelines carry significant weight with patients, payors, and agencies dedicated to cost-efficient and effective care for the population. With an aging society, there is a belief that guidelines for arthritis management will be pivotal. Yet the authors question the utility of guidelines largely based on no evidence, weak evidence and expert opinion. 

The most commonly observed support was the combination of C-level evidence and class II strength (benefit greater than or equal to harm); this was seen in roughly 30% of the guidelines  and in 50% of the RA recommendations.

The quality of ACR guidelines is similar to that seen with other subspecialty guidelines, including cardiology, infectious diseases, nephrology, etc.

The authors point out that some guideline recommendations do have high levels of evidence and strength and that such guidelines merit greater adherence and implementation.

The authors conclude that the evidence supporting ACR recommendations is limited, with more than 50% of  recommendations classified as level C.  While the ACR has adopted the GRADE system of evidence evaluation to control for some of these deficits, the redefinition of level A evidence and the inclusion of real world evidence may improve the certainty, if not applicability, of future guidelines.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – We’re Number One! (8.17.18)

Dr. Cush reviews the articles and news from the last week on RheumNow.com. Info on comorbidities, the down side of steroids, unmet need in psoriatic arthritis and the top 10 Rheumatology programs.

U.S. News 2018-19 Rheumatology Rankings

The Annual U.S. News and World Report Rankings of Hospitals has listed the top contenders in the field of rheumatology. The U.S. News Review rates hospitals nationwide in 16 specialties – including rheumatology. Of the 4,500 hospitals covered by U.S. News that were analyzed, 158 were classified nationally in at least one specialty area.

The RheumNow Week in Review – No Good Gout (8.10.18)

Dr. Jack Cush reviews the news and latest journal articles from the past week on RheumNow.com. Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.

The RheumNow Week in Review – Handshakes or Hugs (8.3.18)

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com, including new treatments for LTBI, gout consequences, RA and offspring risk, PsA risk, and the opioid epidemic effects.

The RheumNow Week in Review – Lupus in the News (7.27.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.